Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joyzyme GroupHKSE:08622 +3.13%40 Current Ratio is 3.88 as of Dec. 2025, which is 25% below its 10-year median of 5.18. GuruFocus rates HKSE:08622 with a GF Score™ of 40/100 and a GF Value™ of HK$0.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 996 Drug Manufacturers companies, Joyzyme Group ranks better than 77.81% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Joyzyme Group's current ratio for the quarter that ended in Dec. 2025 was 3.88.
Joyzyme Group has a current ratio of 3.88. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Joyzyme Group's Current Ratio or its related term are showing as below:
HKSE:08622'
s Current Ratio Range Over the Past 10 Years
Min: 2.36 Med: 5.18 Max: 8.8
Current: 3.88
During the past 11 years, Joyzyme Group's highest Current Ratio was 8.80. The lowest was 2.36. And the median was 5.18.
HKSE:08622's Current Ratio is ranked better than 77.81% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.925
vs HKSE:08622: 3.88
Joyzyme Group (HKSE:08622) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Joyzyme Group Current Ratio Related Terms
Joyzyme Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Joyzyme Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Joyzyme Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joyzyme Group Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Joyzyme Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Joyzyme Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joyzyme Group (HKSE:08622) has a Current Ratio of 3.88 as of Dec. 2025. This is 25% below median its historical median of 5.18. Over the past decade, Joyzyme Group's Current Ratio has ranged from 2.36 to 8.80. According to the industry distribution chart, Joyzyme Group ranks #221 out of 996 companies in the Drug Manufacturers industry, placing it in the top 22.2%.
Is Joyzyme Group's Current Ratio too high?
Joyzyme Group's current Current Ratio of 3.88 is 25% below median its 10-year median of 5.18. Over the past 10 years, this metric has ranged from a low of 2.36 to a high of 8.80. The Drug Manufacturers industry median Current Ratio is 1.93. Joyzyme Group's value of 3.88 is 101.6% above this industry median. Based on the distribution chart, Joyzyme Group ranks #221 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Joyzyme Group has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Joyzyme Group's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joyzyme Group ranks #221 out of 996 companies for Current Ratio. This places Joyzyme Group in the top 22% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.93. Joyzyme Group's value of 3.88 is 101.6% above this benchmark. Historically, Joyzyme Group's own Current Ratio has ranged from 2.36 to 8.80 over the past decade. While the company's 10-year median is 5.18 vs. the industry median of 1.93, Joyzyme Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.93, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joyzyme Group's current Current Ratio of 3.88 is 101.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joyzyme Group's current Current Ratio is 3.88, which is 25% below median its own 10-year median of 5.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joyzyme Group stock overvalued right now?
Based on GuruFocus' analysis, Joyzyme Group (HKSE:08622) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.17, compared to a current price of HK$0.17 — trading 2.9% below its estimated fair value. The current Current Ratio is 3.88, which is 25% below median its 10-year median of 5.18 and 101.6% above the Drug Manufacturers industry median of 1.93. Joyzyme Group's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Joyzyme Group (HKSE:08622), the current Current Ratio is 3.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joyzyme Group (HKSE:08622) Overvalued in 2026?
Based on GuruFocus' analysis, Joyzyme Group stock appears to be undervalued.
The current stock price of HK$0.17 is trading 2.9% below its estimated GF Value™ of HK$0.17.
GuruFocus considers Joyzyme Group to be Fairly Valued.
Key valuation signals for HKSE:08622:
Current Ratio: 3.88 (25% below median its 10-year median of 5.18)
GF Value™: HK$0.17 vs. price of HK$0.17 (2.9% below fair value)
Industry Position: 101.6% above the Drug Manufacturers median (#221 of 996)
No single metric tells the full story. See the HKSE:08622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo.16 Yinkui Road, 1-3 floor and 5th floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Joyzyme Group Ltd is an investment holding company. The Company and its subsidiaries are principally engaged in research and development, manufacture, marketing, and sale of biological reagents and auxiliary reproductive supplies and equipment, and healthcare products and supplements in the People's Republic of China (the PRC). It operates in two segments: Biological reagents and auxiliary reproductive supplies and equipment, and Healthcare products and supplements. It generates the majority of its revenue from the biological reagents and auxiliary reproductive supplies and equipment segment. Geographically, it generates revenue from the PRC.
40GF Score
Get the complete analysis for HKSE:08622
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08622 has been successfully added to your 
